Welcome to the International Society for Vaccines

Skip to main content

Officers and Board Members 2020-2021

Submitted by admin on Thu, 01/23/2020 - 11:45
President

Ted Ross

ISV Fellow of the Month
Country
United States
Portraits
Treasurer

Shan Lu

ISV Fellow of the Month
Country
United States
Portraits
Secretary

Linda Klavinskis

Title
Professor of Viral Immunology, King’s College London
Description

Linda S. Klavinskis, PhD, is Professor of Viral Immunology at King’s College London where her laboratory focuses on immunity to vaccination and virus infection. The goal is to understand and harness cross talk between dendritic cells and T cells, and use this knowledge to develop new and more effective vaccines. This work has led to deciphering an alternative mode of antigen presentation, termed ‘cross-dressing’ and unravelling mechanisms contributing to epitope selection and CD8 T-cell immunodominance. At the translational level, her lab has made contributions to the development of gene delivery systems for DNA and viral-mediated vaccination. More, recently she made inroads in understanding the biology of skin immunisation and developed a microneedle vaccine delivery platform. This has led to the new finding that skin immunisation activates cross talk with innate cells in epithelial barrier tissues to recruit effector CD8+ T-cells and can establish immune surveillance at the barrier tissues. During the COVID-19 pandemic her lab has focused on the role of innate immunity in the hyperinflammatory response in severe COVID-19 and applying therapeutic approaches. Her laboratory has co-authored over 100 peer-reviewed publications.

Professor Klavinskis currently serves as a member of the UK Medical Research Council’s Infection and Immunity Board. She also serves as Associate Editor of Frontiers in Mucosal Immunology and as an Editor of Frontiers in HIV and AIDS. She has served as President of the ‘Medical Research Club’, a prestigious London based biomedical society established 1891 with a focus in infection and immunity. She contributes to national and international peer review in vaccine sciences and as a consultant in industry. She has expertise in executive and senior management positions, including most recently as Vice Dean for Postgraduate Research (Life Sciences and Medicine) at King’s College London. She is a Fellow of the International Society for Vaccines and was elected a Fellow of the Royal College of Pathologists.

Linda Klavinskis has been an active member of the International Society for Vaccines since 2015 and is an elected ISV Fellow. Her service to the ISV includes, membership of the Executive Board since 2018 (where she has championed promoting opportunities for women and junior/early career researcher members in ISV activities); Secretary for the 2020-2021 term; and is President-elect for the 2022-2023 term.

She served as Co-Chair of the 2019 ISV Annual Congress in Ghent, playing a key role in identifying the Scientific Committee (SC) and planning the scientific program with the SC and also introduced further opportunities for junior researchers e.g. the “Bright Sparks in Vaccinology’ junior PI session and a career focus event illustrating opportunities beyond the purely academic career path.  During the COVID-19 pandemic she served as Co-chair for the ISV COVID-19 Vaccine Congress mini-series (2020 -2021). With Drs Shan Lu and Margaret Liu she wrote an article published in Emerging Microbes and Infections, which described the leadership role of the ISV in providing the global community with balanced presentations of progress and challenges in COVID-19 vaccine development.

Over the past 5 years she has annually contributed to the ISV as a workshop chair and as a plenary/workshop speaker. She regularly contributes to the ISV newsletters to publicise and feedback on the ISV’s work. She brings a trans European and North American perspective to the Society from her training and extensive research experience in several labs on these continents.   

ISV Fellow of the Month
Country
United Kingdom
President Elect

Denise Doolan

Denise Doolan
ISV Fellow of the Month
Country
Australia
Portraits
President Emeritus

David Weiner

Title
Director, Vaccine and Immunotherapy Center and Executive Vice President, Wistar Institute; Professor Emeritus, University of Pennsylvania
Description

Dr. David B. Weiner directs a translational molecular immunology research team focused on synthetic nucleic acid-based approaches for disease prevention and treatment.  His group is one of the first research teams in the field of Nucleic Acid Vaccines & Immune Therapies, advancing some of their first clinical trials.  His lab has contributed to multiple aspects and technology developments in advancing DNA vaccines.  Work resulted in clinical studies of an early Zika vaccine, the first MERS vaccine, an advanced Ebola Vaccine, a SARS-CoV2 Vaccine and a novel HIV immunogen platform, among others in the infectious disease arena.  In oncology his laboratory has helped to advance novel immune therapy approaches for HPV disease, prostate disease, GMB immunotherapy which are in clinical testing. This year a therapeutic DNA vaccine (HPV CIN) (VGX3100) moved into a licensure trial (REVEAL).  His lab work is also advancing dMAb in vivo antibody technologies for immune prevention and therapy.

Dr. Weiner’s laboratory has published over 430 papers/chapters & reviews and provided > 450 lectures. He has received several awards/honors, including the WW Smith Family Chair in Cancer Research - 2016, Vaccine Industry Association Outstanding Academic Research Laboratory (2015 & 2016) (runner up 2017, 2018, 2019), Top 20 Translational Research Laboratories of the Year (Nature Biotechnology 2016 - 2020), Stone family award for Cancer Research 2014, NIH Directors Translational Research Award 2011, and the Pennsylvania Life Sciences Achievement Award (2019). He is a Fellow of the American Association for the Advancement of Science 2011 and a Fellow of the International Society for Vaccines 2010.  He served as President of the International Society for Vaccines (2018-2020).  He serves on the Executive Committee of the UPENN CFAR and served as chair of the prestigious Gene Therapy and Vaccine Training Program at the University of Pennsylvania (2004-2016).  He is currently a Wistar Institute Professor, Director of the Vaccine and Immunotherapy Center and the Executive Vice President of the Wistar Institute, and a Professor Emeritus at the University of Pennsylvania.   Dr. Weiner has been an avid teacher, trainer, advisor, and advocate for students, fellows and junior faculty as he is highly committed to developing of the careers of young scientists.  

ISV Fellow of the Month
Country
United States
Board Chairs

Margaret Liu

Description

Professor Margaret A. Liu, obtained an M.D. from Harvard Medical School, a B.A. in Chemistry, summa cum laude, from Colorado College, and passed the Epreuve pour le Diplôme d’Enseignement, à l’unanimité (judges’ unanimous decision), in piano from the Ecole Normale de Musique de Paris, and is the recipient of an honorary Medical Degree (MD honoris causa) from the Karolinska Institutet in Stockholm, and an honorary Doctorate of Science from Colorado College. She completed Internship and Residency in Internal Medicine and a Fellowship in Endocrinology, all at Massachusetts General Hospital/Harvard Medical School. She received Board Certification in Internal Medicine and in Endocrinology and Metabolism. Dr. Liu was a Visiting Scientist at the Massachusetts Institute of Technology, Instructor at Harvard Medical School, Adjunct Assistant Professor of Medicine at the University of Pennsylvania, a Visiting Professor at the Karolinska Institutet in Stockholm, and the recipient of an NIH Physician Scientist Award. She served as Senior Director at Merck Research Laboratories, Vice President of Vaccines Research and Gene Therapy at Chiron Corporation, Vice-Chairman of Transgène, Senior Advisor in Vaccinology at the Bill & Melinda Gates Foundation, Executive Vice-Chair of the International Vaccine Institute, and was on the US NIH NIAID Council.

Her research has focused on novel technologies for vaccines and immune treatments for cancer. She pioneered the development of DNA vaccines, which are now in clinical trials for many human diseases and are licensed for several veterinary applications. She also was an innovator in the field of bispecific antibodies to activate T cells for tumor cell killing. The Nobel Committee invited her to lecture in the Karolinska Research Lecture series, and she was named by Discover magazine as one of the 50 most important female scientists. She consults world-wide for companies, investment firms, non-governmental organizations, and governmental scientific advisory bodies, and has held positions as an Adjunct Professor at UCSF, and as a Foreign Adjunct Professor at the Karolinska Institutet. Dr. Liu was previously the President of the International Society for Vaccines for the 2015- 2017 term, then President Emerita, and is currently the Chairman of the Board of ISV (2020-2021).

ISV Fellow of the Month
Country
United States
Portraits
Board Members

Randy Albrecht

Randy Albrecht
Title
Associate Professor of Microbiology; Director, Emerging Pathogens Facility Icahn School of Medicine at Mount Sinai
Description

Dr. Albrecht earned his Doctor of Philosophy degree in Microbiology and Immunology from the Louisiana State University Health Sciences Center, Shreveport, Louisiana in 2003 under the mentorship of Dr. Dennis J. O'Callaghan. He conducted his postdoctoral studies in the laboratory of Dr. García-Sastre in the Department of Microbiology at the Icahn School of Medicine at Mount Sinai, New York.

Specific areas of research have focused on developing novel influenza vaccines, studying humoral responses of animals and humans to influenza vaccines, developing immunological reagents and assays to examine  the adaptive immune response of ferrets, testing the protective efficacy of novel influenza vaccines in small animal models of influenza disease, and in vitro assays of antibody-mediated virus neutralization. Novel influenza vaccines that induce protective immunity against more conserved antigens such as the hemagglutinin stalk domain are an exciting and rapidly developing area of research on influenza virus vaccines. These vaccine approaches hold the promise to induce broadly neutralizing antibody and cellular immune responses that could confer increased protection against antigenic drift and possibly against  pandemic influenza.  Dr. Albrecht has contributed to preclinical research studies that have examined in the ferret model of influenza the potential of sequential immunization regimens with vaccines that are designed to focus humoral immune responses against the conserved hemagglutinin stalk domain.

 Dr. Albrecht, an active member of ISV, serves as the Editor of the ISV newsletter. Dr. Albrecht served on the Scientific Organizing Committee for the 2018 ISV Annual Congress held in Atlanta, Georgia (USA), and was elected a member of the ISV Board (2020-2021).

ISV Fellow of the Month
Country
United States

Manon Cox

Description

Dr. Manon M.J. Cox, MBA founded NextWaveBio early 2018 initially providing scientific and strategic direction to various biopharmaceutical companies. NextWaveBio’s mission is to bridge the gap between preclinical and clinical development by offering infrastructure and education around quality systems required for clinical development and manufacturing. Prior to that she led the development of Flublok®, the only FDA approved recombinant influenza vaccine at Protein Sciences Corporation where she served as President and Chief Executive Officer since April 2010 and Director since 2008. She joined Protein Sciences in 1998 as Director of Business Development and became Chief Operating Officer in 2003.

Previously she was with Gist-brocades, a large Dutch company specialized in fermentation, where she held various management positions, most recently in New Business Development and before that in Production and Research and Development.  Prior to joining Gist-brocades, she worked as a Molecular Biologist on the development of a PCR screening test for cervical cancer at the University of Amsterdam. 

She serves on the Board of Directors of Vaxxas, the Netherland-America Foundation including its Education Committee, the International Society of Vaccines, and various Scientific Advisory Boards in the vaccine development space.

Dr. Cox has received many honors and awards recognizing her stature as a leader in innovation and influenza, including in 2014 receiving a Doctorate in Humane Letters honoris causa from St. Joseph University and the Woman of Innovation award from the Connecticut Technology Council and was elected fellow in the International Society of Vaccines in 2015. Dr. Cox holds a Doctorate from the University of Wageningen, received her MBA with distinction from the University of Nyenrode and the University of Rochester, NY and holds a Doctorandus degree in Molecular Biology, Genetics and Biochemistry from the University of Nijmegen, The Netherlands.

ISV Fellow of the Month
Country
United States
Portraits

Lars Frelin

Title
Associate Professor/Researcher, Karolinska Institutet
Description

Lars Frelin, PhD, is a senior researcher, associate professor in virology and a principal investigator in the Vaccines and Immunotherapies against Viruses and Cancer (VIVAC) at Karolinska Institutet, Stockholm, Sweden. His research is focused on the development of genetic vaccines for viral hepatitis, specifically for hepatitis B, C and D viruses, but also other infectious diseases like Sars-Cov-2. The research program also aims to establish and evaluate in vivo and in vitro models of the studied infectious diseases to enable appropriate evaluation of vaccine efficacy.  He is also the director for the study program in biomedical laboratory science and the master´s program in diagnostic cytology at Karolinska Institutet.  He teaches undergraduate, graduate and postgraduate students at Karolinska Institutet in the field of microbiology and vaccinology.

Dr. Frelin is an active senior researcher in the field of genetic vaccines, and has published >45 peer-reviewed scientific papers in the field.  He has participated in two clinical trials (phase I/II) using an in-house developed hepatitis C virus DNA-based vaccine in combination with in vivo electroporation.  He has also developed a new pre-clinical multi-needle device for high-speed injection of vaccines into tissues. The device has been evaluated in mice, rabbits and pigs.

Dr. Frelin is a cofounder of the Swedish Vaccine Factory that aims to commercialize genetic vaccines for viral diseases. Currently, the company is developing one immunotherapy for hepatitis B and D and one vaccine for Covid-19.  He is an appointed member of the Infrastructure Committee at Karolinska Institutet and the Steering Committee ANA Futura at Karolinska Institutet.

Gary Kobinger

Title
Professor, Université Laval and Director of the Centre de Recherche en Infectiologie
Description

Dr. Gary Kobinger obtained his PhD magna cum laude from the University of Montreal was recruited by the Public Health Agency of Canada where he became Chief of the Special Pathogens Biosafety Level 4 program. He is now a Professor at the Université Laval and is Director of the Centre de Recherche en Infectiologie. He also holds appointments at the University of Manitoba and the University of Pennsylvania.

Dr. Kobinger supported the development the rVSV-ZEBOV vaccine as well as the monoclonal antibody cocktail ZMapp which was advanced to treat Ebola virus infection, the first such antibody approach advanced for Ebola, thus helping to advance the MAb approach for EID in resource limited settings. His preclinical NHP work and service to WHO helped advance rVSV-ZEBOV, which is an important tool for control of Ebola. He also pioneered simple mobile diagnostic laboratories for field use for Ebola testing during outbreaks facilitating public health controls of outbreaks, and used these diagnostic tools in the current SARS-CoV2 outbreak in Canada. For this and other contributions he has been granted several awards including the 2015 scientist of the year award from Radio Canada (CBC), the Order of Manitoba and the Meritorious Service Cross (civil division) of the Governor General of Canada in 2016, and the Manning principal award in 2017. Dr. Kobinger has co-authored over 300 peer-reviewed scientific manuscripts, and has given numerous invited seminars in Universities, national and international funding agencies, departments of national defenses, the White House, and the World Health Organization (WHO) concerning research on high consequence pathogens and the development of new public health policies and recommendations. His work presently focuses on developing and testing new vaccine platforms and immune treatments against pathogens of high consequences to global public health.

Serving the international community, Gary sits on several committees such as the IHR roster of experts in Viral Haemorrhagic Fever, the WHO’s High Priority Pathogen advisory board, the STAG-IH advisory board to the Deputy Director-General and ad-hoc advisor to the SAGE committee. He has contributed to ISV meeting through speaking, helping to organize sessions, and providing speakers. In addition Dr. Kobinger serves on the ISV Board.

ISV Fellow of the Month
Country
Canada

Margaret Liu

Description

Professor Margaret A. Liu, obtained an M.D. from Harvard Medical School, a B.A. in Chemistry, summa cum laude, from Colorado College, and passed the Epreuve pour le Diplôme d’Enseignement, à l’unanimité (judges’ unanimous decision), in piano from the Ecole Normale de Musique de Paris, and is the recipient of an honorary Medical Degree (MD honoris causa) from the Karolinska Institutet in Stockholm, and an honorary Doctorate of Science from Colorado College. She completed Internship and Residency in Internal Medicine and a Fellowship in Endocrinology, all at Massachusetts General Hospital/Harvard Medical School. She received Board Certification in Internal Medicine and in Endocrinology and Metabolism. Dr. Liu was a Visiting Scientist at the Massachusetts Institute of Technology, Instructor at Harvard Medical School, Adjunct Assistant Professor of Medicine at the University of Pennsylvania, a Visiting Professor at the Karolinska Institutet in Stockholm, and the recipient of an NIH Physician Scientist Award. She served as Senior Director at Merck Research Laboratories, Vice President of Vaccines Research and Gene Therapy at Chiron Corporation, Vice-Chairman of Transgène, Senior Advisor in Vaccinology at the Bill & Melinda Gates Foundation, Executive Vice-Chair of the International Vaccine Institute, and was on the US NIH NIAID Council.

Her research has focused on novel technologies for vaccines and immune treatments for cancer. She pioneered the development of DNA vaccines, which are now in clinical trials for many human diseases and are licensed for several veterinary applications. She also was an innovator in the field of bispecific antibodies to activate T cells for tumor cell killing. The Nobel Committee invited her to lecture in the Karolinska Research Lecture series, and she was named by Discover magazine as one of the 50 most important female scientists. She consults world-wide for companies, investment firms, non-governmental organizations, and governmental scientific advisory bodies, and has held positions as an Adjunct Professor at UCSF, and as a Foreign Adjunct Professor at the Karolinska Institutet. Dr. Liu was previously the President of the International Society for Vaccines for the 2015- 2017 term, then President Emerita, and is currently the Chairman of the Board of ISV (2020-2021).

ISV Fellow of the Month
Country
United States
Portraits

Lenny Moise

Title
Director of Vaccine Research, EpiVax, Inc. and Research Professor, University of Georgia
Description

Lenny Moise, PhD, serves as the Vice President of Research at SeromYx Systems. He earned his PhD from the Department of Molecular and Cellular Biology and Biochemistry at Brown University in Providence, RI, in 2002. His doctoral research in Dr. Edward Hawrot’s laboratory focused on structure-function relationships of snake neurotoxin interactions with the nicotinic acetylcholine receptor. Following his PhD, Dr. Moise pursued postdoctoral training at Brown University, where he delved into the functional analysis of toxin binding sites engineered into toxin-insensitive ion channels. In 2005, he joined Dr. Anne De Groot’s laboratory at Brown University as an Instructor in Medicine in the Department of Medicine (Infectious Disease), where his research centered on T-cell epitope-driven vaccination and protein therapeutic immunogenicity. He joined EpiVax in Providence, RI, in 2006, where he served as the Director of Vaccine Research until 2022. Over this time, he led innovative T cell epitope-driven vaccine development projects, employing a comprehensive genomes-to-vaccine approach that combines immunoinformatic and immunologic methodologies. He also dedicated his efforts to the de-immunization of protein therapeutics through epitope modification. In 2008, Dr. Moise accepted a part-time appointment as Assistant Research Professor in the Department of Cell and Molecular Biology at the University of Rhode Island, becoming a founding faculty member of the URI Institute for Immunology and Informatics, and was promoted to Associate Research Professor in 2014. Additionally, from 2020 to 2022, he was a part-time Research Professor in the Center for Vaccines and Immunology at the University of Georgia. Dr. Moise joined SeromYx in 2022, where he assumed the responsibilities of driving the scientific development of the Systems Serology platform and overseeing the management of both commercial and internally driven research projects.

 

Punnee Pitisuttithum

Title
Director of the Vaccine Trial Centre, Faculty of Tropical Medicine Mahidol University, Thailand
Description

Professor Punnee Pitisuttithum is the Head of the Department of Clinical Tropical Medicine, and also the Head of the Vaccine Trial Centre (VTC) at the Faculty of Tropical Medicine, Mahidol University, Thailand. She is an internationally recognized expert on tropical infectious diseases, especially on vaccine trials and clinical studies. She has completed over 40 clinical trials and has 170 publications in international peer-reviewed journals. Her research has been cited more than 5,000 times according to Scopus database. She has designed and conducted numerous clinical studies (phase I, II, III vaccine trials) of tropical diseases and vaccine against HIV/AIDS, HPV, Cholera, and other infectious diseases. She was the lead clinical investigator in the largest community trial of HIV vaccines (prime-boost regimen) involving 16,000 participants (RV144) which was the first time showed efficacy in human. She played a key role in the testing of the world’s first commercial dengue vaccine.

She served as a member of the Initiative for Vaccine Research (IVR) of the World Health Organization (WHO), the WHO-UNAIDS Vaccine Advisory Committee (VAC) on HIV/AIDS, the International AIDS Vaccine Institutes, and the Task Force on Research and Development during the establishment of The Global Alliance for Vaccines and Immunization (GAVI). She has also chaired and co-chaired numerous international conferences or reviewing committees. She has received numerous honors and awards including the Most Outstanding Researcher in Medical Science in 2015 from the National Research Council of Thailand, as well as the Mahidol University Award for Outstanding Research in 2013.

She received her MBBS degree from Lady Hardinges Medical College, New Delhi, India. She has a Diploma in Tropical Medicine and Hygiene and a Doctor of Clinical Medicine degree, both from Mahidol University, Thailand. She also holds a Diploma of Thai Board of Internal Medicine from the Medical Council of Thailand.

ISV Fellow of the Month
Country
Thailand

Joon Haeng Rhee

Title
Professor of Microbiology, Chonnam National University Medical School
Description

Dr. Joon Haeng Rhee is a graduate of Chonnam National University Medical School and received PhD from the same university. He has been working on molecular microbial pathogenesis and vaccine biology for more than 30 years.

For the molecular microbial pathogenesis studies, his laboratory has been observing the V. vulnificus-host interactions using various molecular and cellular microbiological tools. His team was the first reporter of the whole genome sequence of V. vulnificus, which became one of the most widely used standard strains in the Vibrio research field. They identified an RTX (repeats in toxin) toxin as the culprit of deadly host-killing mechanism in the V. vulnificus infections and recently developed an effective preventive vaccine and therapeutic monoclonal antibody targeting a specific region of the toxin. Vaccine study was first started aiming the high mortality V. vulnificus infections. During the vaccine research, his team came across the finding that a flagellin protein of V. vulnificus has an excellent mucosal adjuvant effect in late 1990s, which was later proved by his group and others to be mediated by the TLR5 signaling. Currently his laboratory is studying the basic science and applications related to the flagellin-TLR5-mediated immune modulation. His team reported the mechanism how TLR5 is very well maintained in senescent animals and proposed that flagellin could be used an effective adjuvant for vaccines against infectious diseases affecting elderly population. Now flagellin is applied to the development of effective vaccines and immunotherapeutics against diverse diseases such as cancers, allergies, and Alzheimer’s disease.

He was the president of Korean Vaccine Society (KVS) from 2013 to 2015. He hosted the 2015 International Society for Vaccines (ISV) Congress in Seoul as a local co-chair. He was elected as an ISV Fellow and serves a member of ISV Executive Board. He served editorial board member for Infection and Immunity and Microbiology and Immunology journals. He is currently the director of Clinical Vaccine R&D Center and Combinatorial Tumor Immunotherapy Research Center of Chonnam National University. As of August 2021, he has more than 160 papers published in peer-reviewed journals and named as an inventor on 20 patents

ISV Fellow of the Month
Country
South Korea

Xavier Saelens

Title
Professor of Biochemistry and Microbiology, Ghent University
Description

Dr. Xavier Saelens obtained his PhD degree from the University of Ghent (Ghent, Belgium) in 1990 in the laboratory of Walter Fiers. After postdoctoral training in the influenza research group of Willy Min Jou, and in the Molecular Signaling and Cell Death group of Peter Vandenabeele, both at Ghent University, he became an assistant professor in Molecular Virology in 2008. Currently, he is a full professor in the Department of Biochemistry and Microbiology at Ghent University and a principle investigator at the VIB-UGent Center for Medical Biotechnology.

The research team of Xavier Saelens applies modern biotechnology methods to develop new vaccines and antivirals against important human respiratory viruses such as influenza, respiratory syncytial virus and, more recently, coronaviruses. In addition, his group uses interactomics tools to gain new insights in the molecular interplay between host and viral factors.

His research group pioneered the development of a universal influenza A vaccine candidate based on the viral matrix protein 2 and elucidated it’s mechanism of protection. More recently, his team proposed a new human respiratory syncytial vaccine candidate that is based on the small hydrophobic protein of this virus. This vaccine candidate has successfully passed a Phase I clinical study. The group also develops single domain antibodies and formats thereof as new candidate biologics to control infections by human respiratory viruses. A recently started research focus point is the development of respiratory delivery technologies for antibody-based antivirals.

In 2015 he received the biennial price in Virology from the Study Centre Princess Joséphine- Charlotte from the Flanders and Walloon Research Foundations of Belgium. In 2019 and 2020 Xavier Saelens obtained excellence awards from VIB for outstanding scientific and technology transfer output.

He is a board member and the treasurer of the Belgian Society for Microbiology and member of the board of the International Society for Vaccines where he has contributed in many ways to the society.

ISV Fellow of the Month
Country
Belgium

Jeffrey Ulmer

Description

Dr. Jeffrey Ulmer has been an active scientist in the vaccines community since completing his post-doctoral fellowship in 1990.  He has published more than 200 scientific papers in various aspects of vaccines discovery and development, is named as a co-inventor on eleven patents, serves on the editorial boards of three journals, and has been on the scientific advisory boards of many academic laboratories and biotechnology companies.  During his career in the vaccines industry, he has held scientific and management positions in the Vaccines divisions of Merck Research Laboratories, Chiron Corporation, Novartis and GSK.  His various leadership roles and responsibilities have included:  Platform Technology Leader (DNA, RNA vaccines), Project Leader (Tuberculosis, SARS); Department Head (Immunology & Cell Biology), Global Function Head (External Research), US Site Head Research, Head Preclinical R&D, and Program Head Technical R&D.

ISV Fellow of the Month
Country
United States